Chemokine (C-X-C motif) receptor 4 (CXCR4) is a key factor for tumor growth and metastasis in several types of human cancer including multiple myeloma (MM). Proof-of-concept of CXCR4-directed radionuclide therapy in MM has recently been reported. This study assessed the diagnostic performance of the CXCR4-directed radiotracer [ 68 Ga]Pentixafor in MM and a potential role for stratifying patients to CXCR4-directed therapies. Thirty-five patients with MM underwent [ 68 Ga]Pentixafor-PET/CT for evaluation of eligibility for endoradiotherapy. In 19/35 cases, [ 18 F]FDG-PET/CT for correlation was available. Scans were compared on a patient and on a lesion basis. Tracer uptake was correlated with standard clinical parameters of disease activity.
Introduction
Multiple myeloma (MM) accounts for approximately 1% of all cancers and around 10% of hematological malignancies [1, 2] . Although overall survival has improved over the last decade, based on the availability of various novel drugs and treatment options, MM essentially remains an incurable disease.
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Chemokine (C-X-C motif) receptor 4 (CXCR4) has been described to play a pivotal role in tumor growth and progression, tumor invasiveness and metastasis [3] . Overexpression of the receptor has been reported in more than 30 different types of cancer [4] [5] [6] [7] . CXCR4 activation has been shown to correlate with MM-related bone disease [8, 9] . Additionally, the interplay between receptor and its ligand stromal derived factor 1 (SDF-1α/CXCL12) serves as a stimulator of plasma cell proliferation [4] .
Recently, a radiolabelled CXCR4-ligand ([ 68 Ga]Pentixafor) for PET imaging has been developed [10, 11] . Dosimetry and proof-of-concept for visualization of CXCR4-expression could be demonstrated in patients with multiple myeloma and other hematologic and solid malignancies [12] [13] [14] [15] . A pilot study further proved the feasibility of CXCR4-directed radionuclide therapy as a novel treatment approach for MM [16] .
In this study, we aimed to further evaluate the performance of [ 68 Ga]Pentixafor-PET/CT in comparison to [ 18 F]FDG-PET/CT, serving as reference. Additionally, we correlated in-vivo CXCR4 expression with cytogenetics and serum markers of diseases activity.
Materials and Methods
[ 68 Ga]Pentixafor was administered on a compassionate use base in compliance with §37 of the Declaration of Helsinki and The German Medicinal Products Act, AMG §13 2b and in accordance with the responsible regulatory body (Regierung von Oberfranken, Bavaria, Germany). All patients had exhausted all alternative treatment options and underwent CXCR4-directed imaging for endoradiotherapy evaluation. All subjects gave written informed consent prior to [ 68 Ga]Pentixafor PET/CT.
Subjects and study design
35 patients (23 males, 12 females, age 44-82 y, mean, 62±8.5 y) with a history of MM were included. All patients had been pre-treated with a number of various chemotherapeutic drug regimens including novel agents such as bortezomib, lenalidomide and others. 28/35 subjects had undergone autologous stem cell transplantation (SCT) before. 
PET/CT imaging
[ 68 Ga]Pentixafor was prepared as previously described [17] . In short, all syntheses were performed in a fully automated, GMP-compliant procedure using a GRP ® module (SCINTOMICS GmbH, Germany) equipped with a disposable single-use cassette kit (ABX, Germany). The eluate ( 68 Ga 3+ in 0.6 M HCl) of a 68 Ge/ 68 Ga-generator (iThemba Labs, Faure, South Africa) was transferred to a cation exchange cartridge, eluted with 5 N NaCl, added to a solution of 40 µg Pentixafor (Scintomics, Fürstenfeldbruck, Germany) in HEPES-buffer and heated for 6 minutes at 125 °C. The product was immobilized on a SepPak C18 cartridge, washed with water und eluted with ethanol/water 50/50. The eluate was passed through a sterile filter (0.22 µm) into a sterile vial und diluted with phosphate buffer solution to a total volume of 15 mL. Radiochemical purity was determined by gradient high performance liquid chromatography and thin-layer chromatography. Additionally, the product was also tested for ethanol content, pH, radionuclide purity, sterility, and endotoxins.
[ 18 Corresponding CT low-dose scans for attenuation correction were acquired using a low-dose protocol (20 mAs, 120 keV, a 512 × 512 matrix, 5 mm slice thickness, increment of 30 mm/s, rotation time of 0.5 s, and pitch index of 0.8) including the base of the skull to the proximal thighs. Consecutively, PET emission data were acquired in three-dimensional mode with a 200 × 200 matrix with 2-3 min emission time per bed position. After decay and scatter correction, PET data were reconstructed iteratively with attenuation correction using a dedicated software (Siemens Esoft, Siemens, Erlangen, Germany).
Image analysis
For [ 18 F]FDG, criteria to define lesions as PET-positive were applied according to Zamagni et al. [13] . For [ 68 Ga]Pentixafor, lesions were visually determined as focally increased tracer retention as compared to surrounding normal tissue or contralateral structures. Presence and number of intra-and extramedullary (EMD) disease as well as location of lesions were recorded. Analysis both on a patient and a lesion basis was performed. SUVmax of the hottest intra-and extramedullary lesion was measured.
Statistical analysis
Statistical analyses were performed using PASW Statistics software (version 22.0; SPSS, Inc. Chicago, IL). Quantitative values were expressed as mean ± standard deviation or median and range as appropriate. Comparisons of related metric measurements were performed using Wilcoxon-signed rank test. The Chi square-or Fisher exact test was conducted for comparison of frequency data between independent subgroups. For bivariate correlation analyses, Spearman or Pearson correlation coefficients were calculated. All statistical tests were performed two-sided and a p-value < 0.05 was considered to indicate statistical significance. No correction for p-values was applied to adjust for multiple tests.
Results

Clinical findings
All patients presented with advanced, active MM. High-risk cytogenetics were documented in 10/21 (47.6%) subjects. Serum FLC ranged from 0.5 to 18.556.0 mg/l (median, 395.8), ß2m from 1.8 to 33 (median, 5.7) and M gradients from 0 to 52.7 g/dl (median, 0). Albumin levels were decreased (<3.5 g/dl) in 8/35 (22.9%) patients. Serum creatinine was increased (>1.2 mg/dl) in 13/35 (37.1%) subjects and LDH in 17/35 (48.6%). Patients´ characteristics are summarized in Table 1 .
Imaging results
[ 68 Ga]Pentixafor-PET was visually positive in 23/35 patients (65.7%, example given in Figure 1 ). In the remaining 12 subjects with serologically active disease, no relevant expression of CXCR4 could be recorded. 
Number and location of intramedullary lesions
Number and location of extramedullary lesions
Presence of CXCR4-positive EMD was associated with both shorter TTP (49±4 d vs. 105±23 d in EMD negative patients; p=0.018) and OS (169±36 d vs. not reached; p<0.0001; Figure 2 ). Of note, the number of EMD lesions had a prognostic value, regarding both TTP (p= 0.055) and OS (p<0. SUVmax of the hottest CXCR4 positive intramedullary lesions ranged from 4.1 to 57.4 (median, 16.4), maximum uptake of the hottest CXCR4 positive extramedullary lesion from 5.0 to 67.1 (median, 14.9). In comparison, SUVmax of the hottest intramedullary lesions in FDG images ranged from 3.8 to 40.1 (median, 11.6), maximum FDG-uptake of the hottest extramedullary lesion from 5.0 to 37.7 (median, 9.0). OS and TTP did not differ significantly if patients were stratified based on the median uptake of CXCR4-and FDG-positive intraand extramedullary lesions.
Correlation of imaging parameters with laboratory findings and cytogenetics
[ 68 Ga]Pentixafor-PET positivity was independent from all laboratory parameters investigated including LDH, albumin, creatinine, ß2M, M gradient or the level of free serum light chains as well as the cytogenetic risk profile and myeloma type.
Discussion
This is one of the first investigations indicating that expression of the chemokine receptor 4 (CXCR4) is a frequent event in multiple myeloma (MM) and can be non-invasively assessed by PET/CT and the CXCR4-directed radiopharmaceutical [ 68 Ga]Pentixafor. About two-thirds of patients with advanced disease show multiple, CXCR4-expressing myeloma lesions. Moreover, previously unknown manifestation sites could be visualized in 21% of patients using this innovative imaging modality. This result is in line with a recent in-vitro analysis reporting CXCR4 overexpression on the cell membrane of myeloma cells in 56% of cases [12] .
In our cohort, CXCR4-positivity was independent from myeloma subtype, M protein and free serum light chain levels or presence of high-risk cytogenetics. Of note, CXCR4 expression of MM proved as a significant predictor of shorter TTP and OS. As expected, presence and extent of CXCR4 + EMD was associated with pronouncedly reduced survival. patients were CXCR4-negative despite metabolically active disease, as identified by FDG-PET. In the remaining 4/19 (21%) subjects receiving imaging with both PET tracers, an intra-individual heterogeneity of receptor expression was noted with a mixture of both CXCR4 + and CXCR4 -lesions. The biologic implications of this finding are not fully understood yet. One hypothesis speculated on potential inferiority of [ 68 Ga]Pentixafor-PET in extramedullary disease due to reduced CXCR4 expression and its critical role in cell homing [18, 19] . Another recent publication hinted at a special role of CXCR4 in the acquisition of an epithelial-to-mesenchymal transition-like phenotype, which promotes MM cell dissemination [20] .
Given the fact that metabolic PET tracers including [ 11 [25] .
In our cohort, the majority of heavily pre-treated patients qualified for CXCR4-directed therapy with a therapeutic counterpart allowing for labelling with both α-and β-emitters ( 90 Y-or 177 Lu-labelled Pentixather). Proof-of-concept in advanced stage MM patients could recently be demonstrated by our group [16] . Of note, CXCR4-directed treatment is only performed if the whole tumor cell compartment can be targeted by endoradiotherapy (ERT). Since pronounced intraindividual heterogeneity of receptor expression in different lesions can occur, we generally obtain an additional [ 18 F]FDG-PET scan as reference for viable myeloma lesions and to exclude CXCR4-negative lesions which cannot be effectively treated by ERT. A prospective, multi-center trial in Germany will further evaluate the feasibility and benefit of radionuclide therapy in MM (COLPRIT, Eudra-CT 2015-001817-28). Additionally, anti-CXCR4 therapies using non-radioactive agents, such as BMS-936564/MDX-1338, a fully human anti-CXCR4 antibody, are currently under clinical investigation [26] . Given the increasing significance of multi-modal treatment approaches, combinations of novel agents, conventional chemotherapy or other receptors which are highly expressed in MM (e.g. CD38, SLAMF7, CD40) and radionuclide based therapies can be speculated on to yield synergistic effects and raise the hope for even more effective individualized treatment in the future. Yet, little is known about the influence of conventional chemotherapeutic drugs and/or novel agents on CXCR4 surface expression and regulation. Initiation of potent treatment regimens can rapidly downregulate CXCR4 and thereby severely hamper receptor-directed therapies [15] . Further analysis of regulators depressing or enhancing CXCR4 surface density is therefore urgently needed.
The data presented have several limitations. In this cohort, [ 68 Ga]Pentixafor-PET/CT imaging has been performed on a compassionate use base. Hence, this study has to be considered as a retrospective analysis, which comprises only a limited number of patients and is -due to its retrospective nature-prone to selection bias. Furthermore, not all patients received imaging with both radiotracers, preventing a more detailed comparison of the performance of [ 68 Ga]Pentixafor compared to the clinically used radiotracer [ 18 F]FDG. Also, not all positive MM lesions, especially extramedullary manifestations, were histologically proven. Therefore, there might be a false positive rate, e.g. regarding lymph node involvement. Distinct biological features of MM lesions presenting as CXCR4 + /FDG -and vice versa were not investigated. It is not clear if -and to which extent -individual treatment decisions based of PET/CT imaging might have influenced patients' overall prognosis. It can be hypothesized that switching a patient to a more intensive treatment regimen based on PET/CT findings might have resulted in more favourable outcomes. Treatment-induced bias due to heterogeneous treatments at relapse cannot be excluded in this series and may account for some of the prognostic differences that were found. The prognosis of lesions displaying high [ 68 Ga]Pentixafor and low [ 18 F]FDG uptake and how these lesions respond to current treatments has not been clarified yet. Further prospective studies also regarding the prognostic value of CXCR4-expressing disease in terms of therapy monitoring are highly warranted.
In conclusion, [ 68 Ga]Pentixafor-PET enables non-invasive detection of CXCR4 expression which occurs frequently in multiple myeloma. Our data suggest that CXCR4 expression represents a negative prognostic factor and is a potential target for myeloma specific treatment. Additionally, in a significant proportion of patients (21%) previously unknown myeloma lesions have been detected. Currently, selecting patients for CXCR4 directed therapies and prognostic stratification seem to be more relevant clinical applications than diagnostic imaging of myeloma.
